Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALLOPURINOL vs FEBUXOSTAT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Allopurinol inhibits xanthine oxidase, the enzyme responsible for the conversion of hypoxanthine to xanthine and xanthine to uric acid, thereby reducing serum and urinary uric acid concentrations. It also inhibits de novo purine synthesis through feedback inhibition.
Febuxostat is a non-purine selective inhibitor of xanthine oxidase (XO). It inhibits both oxidized and reduced forms of XO, thereby reducing the conversion of hypoxanthine to xanthine and xanthine to uric acid, leading to decreased serum uric acid levels.
Gout (management of recurrent uric acid stones),Hyperuricemia associated with malignancy (tumor lysis syndrome),Uric acid nephropathy,Prevention of calcium oxalate calculi in hyperuricosuric patients,Recurrent uric acid stones,Gouty arthritis (prophylaxis of acute attacks),Secondary hyperuricemia (various causes)
Chronic management of hyperuricemia in patients with gout,Off-label: Prevention of tumor lysis syndrome,Off-label: Management of hyperuricemia in kidney transplant recipients
100-600 mg orally once daily; initial 100 mg/day with weekly increases of 100 mg/day; maximum 800 mg/day.
40 mg orally once daily; may increase to 80 mg orally once daily if serum urate goal not achieved after 2 weeks.
Allopurinol: 1–2 hours; oxypurinol: 18–30 hours (prolonged in renal impairment).
Terminal elimination half-life: 5-8 hours in healthy subjects; prolonged in renal impairment (e.g., up to 9.6 hours in moderate impairment). Clinical context: dosing interval is once daily, consistent with half-life.
Allopurinol is metabolized primarily by aldehyde oxidase to its active metabolite oxypurinol (alloxanthine), which also inhibits xanthine oxidase. Oxypurinol is further metabolized and eliminated renally.
Primarily metabolized by conjugation via UDP-glucuronosyltransferases (UGT1A1, UGT1A3, UGT1A9, and UGT2B7) and oxidation via cytochrome P450 (CYP) enzymes, including CYP1A2, CYP2C8, and CYP2C9, with minor contribution from CYP3A4/5.
Renal: ~76% as unchanged drug and metabolites; oxypurinol (active metabolite) is primarily excreted renally. Biliary/fecal: minor, <5%.
Renal: 1-3% unchanged; biliary/fecal: ~50% as metabolites (acyl glucuronides, oxidative metabolites); other: ~49% metabolized and eliminated via multiple pathways including biliary and direct intestinal excretion of unchanged drug.
Allopurinol: <1%; oxypurinol: ~50% (mainly to albumin).
99% (primarily to albumin; minor binding to alpha-1-acid glycoprotein).
Allopurinol: ~1.6 L/kg; distributes into total body water.
Approximately 0.7 L/kg (indicating distribution into total body water; not extensively tissue-bound).
Oral: ~79–90% for allopurinol; oxypurinol is formed rapidly via first-pass metabolism.
Oral: at least 49% (absolute bioavailability not established; estimated based on mass balance studies).
GFR >50: no adjustment; GFR 10-50: 200 mg/day; GFR <10: 100 mg/day or dosing interval every 48-72 hours.
No dose adjustment required for mild to moderate renal impairment (e GFR 30-89 m L/min). For severe renal impairment (e GFR <30 m L/min), limited data; use with caution, not recommended in dialysis.
No specific guidelines; use with caution in severe hepatic impairment (Child-Pugh C); consider dose reduction.
Child-Pugh Class A or B: no dose adjustment. Child-Pugh Class C: not recommended (no studies).
Children <6 years: 150 mg/day; 6-10 years: 300 mg/day; 11-16 years: 300-600 mg/day; initial dose 10 mg/kg/day divided in 2-3 doses, max 300 mg/day.
Not approved for pediatric use; safety and efficacy not established.
Start at lowest dose (100 mg/day) and titrate slowly; monitor renal function and adjust per GFR.
No specific dose adjustment required; use with caution due to potential for decreased renal function.
No FDA black box warning.
Increased risk of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent revascularization in patients with established cardiovascular disease (based on the CARES trial). Febuxostat should be avoided in patients with a history of myocardial infarction or stroke, unless no other therapy is appropriate.
Hypersensitivity reactions (including Stevens-Johnson syndrome, toxic epidermal necrolysis) occur more frequently in patients with renal impairment or thiazide diuretic use.,Discontinue at first sign of rash or other signs of hypersensitivity.,Increased risk of bone marrow suppression in patients with renal impairment.,Hepatotoxicity (monitor liver function tests).,Acute gout flare may occur during initiation; prophylaxis with colchicine or NSAIDs recommended.,Dose adjustment required in renal impairment.,Azathioprine or 6-mercaptopurine dose reduction required due to inhibited metabolism.
Cardiovascular events (see black box warning); hepatotoxicity (elevated liver enzymes, hepatic failure); gout flares upon initiation (prophylaxis recommended); renal impairment (dose adjustment for severe impairment); hypersensitivity reactions (including Stevens-Johnson syndrome); thyroid function abnormalities (elevated TSH).
Hypersensitivity to allopurinol or any component of the formulation.,Idiopathic hemochromatosis (relative contraindication due to potential for increased iron storage).,Concurrent use with didanosine (increased risk of pancreatitis and peripheral neuropathy).
Concurrent use with azathioprine, 6-mercaptopurine, or theophylline (due to risk of toxicity); severe renal impairment (Cr Cl <30 m L/min) based on trial data; history of myocardial infarction or stroke (relative contraindication per FDA).
Avoid high-purine foods such as organ meats (liver, kidney), anchovies, sardines, mussels, and scallops; limit red meat and shellfish; avoid excessive alcohol, especially beer and spirits; maintain adequate fluid intake.
No specific food interactions are reported, but high-purine foods (red meat, organ meats, shellfish) and alcohol may increase serum urate and counteract drug efficacy; advise moderation and limit intake during therapy.
FDA Pregnancy Category C. First trimester: limited human data, no clear teratogenic signal; animal studies show fetal anomalies at high doses. Second/third trimester: potential for neonatal complications (e.g., hypersensitivity, rash) if used near term; avoid if possible.
Pregnancy Category C. No adequate studies in pregnant women. In animal studies, febuxostat caused developmental toxicity (reduced fetal weight, increased skeletal variations) at maternal toxic doses. First trimester: unknown risk; avoid unless benefits outweigh risks. Second/third trimester: limited data; potential for fetal harm based on animal findings.
Excreted in breast milk; M/P ratio ~0.9. Relative infant dose ~1-2% of maternal weight-adjusted dose. Considered compatible with breastfeeding; monitor infant for rash or diarrhea.
Excretion in human milk unknown; M/P ratio not determined. Due to potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during therapy.
Pregnancy can increase renal clearance and plasma volume, potentially lowering drug levels. Monitor serum uric acid and symptomatic response; dose adjustment may be needed, but data insufficient for specific recommendations. Use lowest effective dose.
No specific pharmacokinetic data in pregnancy. Due to potential teratogenicity, avoid in pregnancy. If use is unavoidable, no dose adjustment studies exist; use lowest effective dose with caution.
Start at low dose (100 mg/day) and titrate every 2-4 weeks to reduce risk of gout flare; check renal function before dosing and adjust accordingly; allopurinol hypersensitivity syndrome (AHS) is rare but life-threatening, discontinue immediately if rash or signs of hypersensitivity occur; avoid use with azathioprine or 6-mercaptopurine unless dose of these agents is reduced by 60-80%; monitor liver function tests periodically.
Febuxostat is a non-purine selective xanthine oxidase inhibitor indicated for chronic management of hyperuricemia in gout. It is contraindicated with concomitant azathioprine, mercaptopurine, or theophylline due to risk of toxicity. Initiate at 40 mg daily; titrate to 80 mg if serum urate not at target after 2 weeks. Monitor for gout flares during initiation; provide prophylactic NSAIDs or colchicine for at least 6 months. Cardiovascular risk: increased risk of cardiovascular death vs allopurinol in patients with history of CV disease; avoid as first-line or in patients with prior MI or stroke. Assess liver function tests at baseline and periodically; discontinue if persistent elevation >3x ULN or signs of liver injury. Not recommended in patients with severe hepatic impairment (Child-Pugh C).
Take exactly as prescribed, usually once daily with food.,Do not stop or change dose without consulting your doctor.,Report any rash, hives, itching, or swelling of face/lips immediately.,Drink plenty of fluids (8-10 glasses per day) to prevent kidney stones.,Avoid alcohol, especially beer, as it may increase uric acid levels.,It may take weeks or months to prevent gout attacks; do not skip doses.,During initial therapy, gout attacks may still occur; continue treatment as directed.,Store at room temperature away from moisture and heat.
Take exactly as prescribed; do not skip doses or stop without consulting your doctor.,You may experience gout flares during the first few months; continue your medication and take prescribed anti-inflammatory drugs as directed.,Report any signs of heart attack or stroke (chest pain, shortness of breath, weakness on one side of body, slurred speech) immediately.,Avoid alcohol, especially beer, which can increase uric acid levels and trigger gout flares.,Inform your doctor if you are taking azathioprine, mercaptopurine, or theophylline; these are not safe to take with febuxostat.,If you have a history of heart attack, stroke, or heart disease, discuss alternative treatments with your doctor.,Seek medical attention for signs of liver injury (yellow skin/eyes, dark urine, abdominal pain, persistent nausea).,Stay hydrated to help prevent kidney stones; aim for 8-10 glasses of water daily unless otherwise advised.,Do not crush or chew tablets; swallow whole with water.
"Concurrent use of bumetanide, a loop diuretic, and allopurinol, a xanthine oxidase inhibitor, may increase the risk of allopurinol hypersensitivity reactions, including Stevens-Johnson syndrome and acute gout flares. This interaction is thought to result from bumetanide-induced volume depletion and reduced renal clearance of oxypurinol, the active metabolite of allopurinol, leading to elevated serum oxypurinol levels and enhanced toxicity. Clinically, patients may present with rash, fever, eosinophilia, or acute gouty arthritis, particularly in those with renal impairment."
"The combination of allopurinol and captopril increases the risk of hypersensitivity reactions, including Stevens-Johnson syndrome and angioedema, due to a pharmacodynamic interaction that potentiates immune-mediated adverse effects. This is particularly concerning in patients with renal impairment, where both drugs may accumulate, and can lead to severe cutaneous adverse reactions or hematologic toxicities."
"Allopurinol inhibits xanthine oxidase, an enzyme involved in the catabolism of purine analogs. Tegafur is a prodrug of 5-fluorouracil and is metabolized via the same pathway. Coadministration of allopurinol may reduce the conversion of tegafur to its active metabolite, thereby decreasing the therapeutic efficacy of tegafur. This can lead to suboptimal antineoplastic effect and potential treatment failure."
"Mercaptopurine is metabolized by xanthine oxidase. Febuxostat inhibits xanthine oxidase, leading to significantly reduced clearance of mercaptopurine and its active metabolites. This can result in severe myelosuppression, including life-threatening neutropenia and thrombocytopenia, as well as hepatotoxicity."
"The serum concentration of the active metabolites of Aminophylline can be increased when Aminophylline is used in combination with Febuxostat."
"The serum concentration of Febuxostat can be increased when it is combined with Azathioprine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALLOPURINOL vs FEBUXOSTAT, answered by our medical review team.
ALLOPURINOL is a Xanthine Oxidase Inhibitor that works by Allopurinol inhibits xanthine oxidase, the enzyme responsible for the conversion of hypoxanthine to xanthine and xanthine to uric acid, thereby reducing serum and urinary uric acid concentrations. It also inhibits de novo purine synthesis through feedback inhibition.. FEBUXOSTAT is a Xanthine Oxidase Inhibitor that works by Febuxostat is a non-purine selective inhibitor of xanthine oxidase (XO). It inhibits both oxidized and reduced forms of XO, thereby reducing the conversion of hypoxanthine to xanthine and xanthine to uric acid, leading to decreased serum uric acid levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALLOPURINOL and FEBUXOSTAT depend on the specific clinical indication. These are both Xanthine Oxidase Inhibitor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALLOPURINOL is: 100-600 mg orally once daily; initial 100 mg/day with weekly increases of 100 mg/day; maximum 800 mg/day.. The standard adult dose of FEBUXOSTAT is: 40 mg orally once daily; may increase to 80 mg orally once daily if serum urate goal not achieved after 2 weeks.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALLOPURINOL and FEBUXOSTAT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALLOPURINOL is classified as Category C. FDA Pregnancy Category C. First trimester: limited human data, no clear teratogenic signal; animal studies show fetal anomalies at high doses. Second/third trimester: potential for. FEBUXOSTAT is classified as Category C. Pregnancy Category C. No adequate studies in pregnant women. In animal studies, febuxostat caused developmental toxicity (reduced fetal weight, increased skeletal variations) at ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.